Intellia Therapeutics reported mixed Phase 2 results for its CRISPR-based therapy NTLA-2002, aimed at treating hereditary angioedema. The study showed a 75% to 77% reduction in attacks among patients, with some remaining attack-free for months post-treatment. Despite a 20% drop in shares, experts highlight the therapy's potential as a one-time curative option, contrasting it with traditional treatments.
Seems like the connection with the server has been lost. It can be due to poor or broken network. Please hang on while we're trying to reconnect...
Oh snap! Failed to reconnect with the server. This is typically caused by a longer network outage, or if the server has been taken down. You can try to reconnect, but if that does not work, you need to reload the page.
Oh man! The server rejected the attempt to reconnect. The only option now is to reload the page, but be prepared that it won't work, since this is typically caused by a failure on the server.
